This article is more than 5 years old. Information may no longer be current.

FDA Approves Dexcom G5 Mobile Continuous Glucose Monitoring System

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The U.S. Food and Drug Administration has approved the first continuous glucose monitoring system sends glucose data directly to a smartphone without the need to carry a separate receiver. The Dexcom G5 Mobile Continuous Glucose Monitoring System has wireless Bluetooth technology built into the device transmitter.

The new transmitter sends glucose information directly to an app on iOS-enabled devices for real-time diabetes management. Android applications will follow early next year, the company said. Like its predecessor, the G4 PLATINUM CGM with Share, users can also select up to five designated recipients, or "followers".  These followers can remotely monitor a patient's glucose information and receive alert notifications.

The G5 Mobile system is anticipated to begin shipping in late September 2015.